Patent ID: 6337325
Filing Date: 2002-01-08
Classification: A61K,A61P,Y10S

Abstract:
A method of obtaining a superadditive immunosupressive effect in a patient with an acute immunological event, an autoimmune disease, dermatitis, urticaria, rhinitis, uveitis, type II diabetes, cystic fibrosis, colitis or fibrosis of the liver by administering:a) at least one compound which has a phosphodiesterase-inhibiting action, selected from the group consisting of 10H-phenothiazine, (3&agr;,16&agr;)-eburnamenine-14-carboxylic acid ethyl ester, 6-(4-(1-cyclohexyl-1-methyl-amino)-4-one-butoxyl)-2(1H)-quinolinone, 1,6-dihydro-2-methyl-6-oxo-(3,4â€²-bipyridine)-5-carbonitrile, 4H-pyrimido(6,1-a)isoquinolin-4-one 2,3,6,7-tetrahydro-9,10-dimethoxy-3-methyl-2-((2,4,6-trimethylphenyl)imino)monohydrochloride, 6-(3,3-dimethyl-2-oxo-indan-5-yl)-4,5-dihydro-2H-pyridazin-3-one, (R)-6-chloro-1,5-dihydro-3-methylimidazo(2,1-b)quinazolin-2(3H)-one, 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidine, 4-(3-(cyclopentoxy)-4-methoxyphenyl)-2-pyrrolidinone, 2-(2-propyloxyphenyl)-8-azapurin-6-one, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline and xanthine derivatives, wherein said xanthine derivative is 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione, 3-isobutyl-1-methylxanthin or 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; and b) at least one compound which reduces the biologically effective intracellular Ca2+ content, selected from the group consisting of dihydropyridines, wherein said dihydropyridine is 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-(methyl-(phenylmethyl)amino)ethyl ester, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester, 3-(benzyl(phenyl)amino)ethyl-5-(5,5-dimethyl-2-oxo-1,3-dioxaphosphorinane-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine, 2-(7-amino-2,5-dioxaheptyl)-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine, 2-(2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester or 3,5-pyridinedicarboxylic acid 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-ethyl-2-(1-piperidinyl)ethyl ester monohydrochloride, benzothiazepines, wherein said benzothiazepine is (2S-cis)-3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one, (E)-1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperzine, 8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one, 3,4-dimethoxy-N-methyl-N-(3-(4-((2-(1-methylethyl)-1-indolizinyl)sulfonyl)phenoxy)propyl)-benzeneethanamine, (8&bgr;)-10-methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyridinecarboxylate or &agr;-hydroxybenzeneacetic acid 3,3,5-trimethylcyclohexyl ester; aminoglycoside-based antibiotics, wherein said aminoglycoside-based antibiotic is neomycin, gentamycin or kanamycin; Ca2+ antagonists, wherein said Ca2+ antagonist is 1,2-bis-(2-aminoethoxyethane)-N,N,Nâ€²,Nâ€²-tetraacetic acid; and inhibitors of intracellular Ca2+ mobilization, wherein said inhibitor of intracellular Ca2+ mobilization is 3-(1H-pyrrole-2-carboxylate, 1-(((5-(4-nitrophenyl)-3-furanyl)-methylene)amino)-2,4-imidazolidinedione, 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate hydrochloride or (5-isoquiniloninesulfonyl)-homopiperazine; to obtain said superadditive immunosuppressive effect in said patient.